What Does Encompass Health Corporation's (NYSE:EHC) Share Price Indicate?

Let's talk about the popular Encompass Health Corporation (NYSE:EHC). The company's shares saw significant share price movement during recent months on the NYSE, rising to highs of US$104 and falling to the lows of US$91.05. Some share price movements can give investors a better opportunity to enter into the stock, and potentially buy at a lower price. A question to answer is whether Encompass Health's current trading price of US$98.03 reflective of the actual value of the large-cap? Or is it currently undervalued, providing us with the opportunity to buy? Let’s take a look at Encompass Health’s outlook and value based on the most recent financial data to see if there are any catalysts for a price change.

Check out our latest analysis for Encompass Health

Advertisement

What's The Opportunity In Encompass Health?

According to our price multiple model, which makes a comparison between the company's price-to-earnings ratio and the industry average, the stock price seems to be justfied. In this instance, we’ve used the price-to-earnings (PE) ratio given that there is not enough information to reliably forecast the stock’s cash flows. We find that Encompass Health’s ratio of 21.54x is trading slightly below its industry peers’ ratio of 23.67x, which means if you buy Encompass Health today, you’d be paying a reasonable price for it. And if you believe Encompass Health should be trading in this range, then there isn’t much room for the share price to grow beyond the levels of other industry peers over the long-term. Furthermore, Encompass Health’s share price also seems relatively stable compared to the rest of the market, as indicated by its low beta. This may mean it is less likely for the stock to fall lower from natural market volatility, which suggests less opportunities to buy moving forward.

What kind of growth will Encompass Health generate?

earnings-and-revenue-growth
NYSE:EHC Earnings and Revenue Growth February 13th 2025

Investors looking for growth in their portfolio may want to consider the prospects of a company before buying its shares. Although value investors would argue that it’s the intrinsic value relative to the price that matter the most, a more compelling investment thesis would be high growth potential at a cheap price. Encompass Health's earnings over the next few years are expected to increase by 30%, indicating a highly optimistic future ahead. This should lead to more robust cash flows, feeding into a higher share value.

What This Means For You

Are you a shareholder? It seems like the market has already priced in EHC’s positive outlook, with shares trading around industry price multiples. However, there are also other important factors which we haven’t considered today, such as the financial strength of the company. Have these factors changed since the last time you looked at EHC? Will you have enough confidence to invest in the company should the price drop below the industry PE ratio?

Are you a potential investor? If you’ve been keeping tabs on EHC, now may not be the most optimal time to buy, given it is trading around industry price multiples. However, the positive outlook is encouraging for EHC, which means it’s worth further examining other factors such as the strength of its balance sheet, in order to take advantage of the next price drop.

So if you'd like to dive deeper into this stock, it's crucial to consider any risks it's facing. Every company has risks, and we've spotted 1 warning sign for Encompass Health you should know about.

If you are no longer interested in Encompass Health, you can use our free platform to see our list of over 50 other stocks with a high growth potential.

Valuation is complex, but we're here to simplify it.

Discover if Encompass Health might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About NYSE:EHC

Encompass Health

Provides post-acute healthcare services in the United States and Puerto Rico.

Very undervalued with outstanding track record.

Advertisement

Weekly Picks

DA
davidlsander
UBI logo
davidlsander on Ubisoft Entertainment ·

Is Ubisoft the Market’s Biggest Pricing Error? Why Forensic Value Points to €33 Per Share

Fair Value:€33.887.7% undervalued
34 users have followed this narrative
3 users have commented on this narrative
19 users have liked this narrative
TO
Tokyo
MC logo
Tokyo on LVMH Moët Hennessy - Louis Vuitton Société Européenne ·

EU#4 - Turning Heritage into the World’s Strongest Luxury Empire

Fair Value:€750.0428.5% undervalued
4 users have followed this narrative
0 users have commented on this narrative
9 users have liked this narrative
WE
WealthAP
GOOGL logo
WealthAP on Alphabet ·

The "Easy Money" Is Gone: Why Alphabet Is Now a "Show Me" Story

Fair Value:US$386.4313.8% undervalued
62 users have followed this narrative
1 users have commented on this narrative
19 users have liked this narrative

Updated Narratives

FU
FundamentallySarcastic
CCP logo
FundamentallySarcastic on Credit Corp Group ·

Moderation and Stabilisation: HOLD: Fair Price based on a 4-year Cycle is $12.08

Fair Value:AU$12.567.8% undervalued
16 users have followed this narrative
1 users have commented on this narrative
0 users have liked this narrative
AN
andre_santos
NOVO B logo
andre_santos on Novo Nordisk ·

Novo Nordisk - A Fundamental and Historical Valuation

Fair Value:DKK 322.435.5% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
DA
davidlsander
UBI logo
davidlsander on Ubisoft Entertainment ·

Is Ubisoft the Market’s Biggest Pricing Error? Why Forensic Value Points to €33 Per Share

Fair Value:€33.887.7% undervalued
34 users have followed this narrative
3 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

WE
WealthAP
PYPL logo
WealthAP on PayPal Holdings ·

The "Sleeping Giant" Stumbles, Then Wakes Up

Fair Value:US$8250.0% undervalued
86 users have followed this narrative
6 users have commented on this narrative
35 users have liked this narrative
OO
NEO logo
OOO97 on Neo Performance Materials ·

Undervalued Key Player in Magnets/Rare Earth

Fair Value:CA$25.3321.7% undervalued
75 users have followed this narrative
0 users have commented on this narrative
19 users have liked this narrative
AN
AnalystConsensusTarget
NVDA logo
AnalystConsensusTarget on NVIDIA ·

NVDA: Expanding AI Demand Will Drive Major Data Center Investments Through 2026

Fair Value:US$253.0231.2% undervalued
1051 users have followed this narrative
6 users have commented on this narrative
32 users have liked this narrative
Advertisement